Research Cluster
Longevity & Anti-Aging Peptides
Longevity is the research area where the distance between compelling preclinical data and actionable human evidence is largest—and where that distance is most consistently obscured in popular coverage. Several compounds in this cluster have generated genuine scientific excitement based on animal data or mechanistic plausibility. That excitement is worth reporting honestly. It is not the same as clinical evidence in humans.
This cluster spans thymic peptide bioregulators with decades of Russian clinical data, mitochondria-targeting compounds with Western Phase II trials, senolytics with striking mouse results and no human data, and observational evidence that certain endogenous peptides decline with age. Each of these is a different category of evidence. The tier system on this page is doing real work.
Cluster at a Glance
10 compounds • 0 FDA-approved • 2 with Phase II/clinical programs • 4 pilot/limited human data • 4 preclinical only
Clinical Trials
Pilot / Human Data
Preclinical Only
Editorial note: Several compounds in this cluster have no human trial data at any dose for any indication. Observational evidence that a peptide declines with age does not establish that replacing it extends lifespan or healthspan. Mechanistic plausibility in rodents does not establish human efficacy. These distinctions are applied consistently throughout.
DSIP: Delta Sleep-Inducing Peptide Research and Evidence
Nonapeptide (WAGGDASGE) discovered in sleeping rabbit brain. 1980s human sleep studies showed inconsistent results. No identified receptor after 45+ years of research.
Read the research →
Epitalon: Telomerase Activation and the Bioregulator Hypothesis
Synthetic tetrapeptide (AEDG) claimed to activate telomerase via pineal gland modulation. From Khavinson's bioregulator program. No human clinical trials—all evidence is preclinical or observational.
Read the research →
FOXO4-DRI: The Senolytic Peptide That Changed the Conversation
D-retro-inverso peptide that disrupts FOXO4-p53 binding to trigger senescent cell apoptosis. One landmark mouse study (Baar et al., 2017). Zero human data.
Read the research →
GDF11: The Parabiosis Factor That Divided Aging Research
TGF-beta superfamily member identified in parabiosis studies as a potential rejuvenation factor. Findings contested between Wagers and Lee labs. No human trials.
Read the research →
Humanin: The Mitochondrial-Derived Peptide Behind the Cytoprotection Research
24-amino-acid mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties. Endogenous levels decline with age. No human trials for exogenous administration.
Read the research →
Klotho Peptide: Anti-Aging Mechanisms, Evidence, and the Research Gap
Fragment of the Klotho anti-aging protein. Dubal lab showed cognitive enhancement in mice (2023). Full-length Klotho is 130 kDa—not a peptide. No human interventional data.
Read the research →
MOTS-c: The Mitochondrial Peptide That Tells Your Cells to Burn
Mitochondrial-derived peptide activating AMPK-mediated metabolic regulation. Exercise mimetic in rodent models. No human clinical trials for exogenous use.
Read the research →
Pinealon: The Pineal Tripeptide and Bioregulator Research
Synthetic tripeptide (Glu-Asp-Arg) from Khavinson's laboratory, claimed to modulate melatonin synthesis and neuroprotection. No human clinical trials.
Read the research →
SS-31 (Elamipretide): Mitochondrial Medicine in Clinical Development
Cardiolipin-targeting mitochondrial peptide. Phase III Barth syndrome trial (TAZPOWER) failed primary endpoint. Stealth BioTherapeutics dissolved. Mechanism validated, clinical program stalled.
Read the research →
Thymalin: Thymic Peptide Bioregulator and Immunosenescence
Thymic polypeptide extract from Khavinson's bioregulator program. Approved and widely used in Russian medicine since the 1980s. Limited Western clinical data.
Read the research →
How These Compounds Relate
The ten compounds in this cluster address longevity through four distinct biological axes. SS-31 and MOTS-c target mitochondrial function directly—the former via cardiolipin stabilization and ROS reduction, the latter via AMPK activation and metabolic efficiency. Humanin is also mitochondrial-derived, making the mitochondria-to-longevity hypothesis a recurring theme across three compounds in this cluster. This convergence is not coincidental: mitochondrial dysfunction is one of the most consistently cited hallmarks of aging in the scientific literature.
Thymosin Alpha-1 and Thymalin both address immune senescence—the progressive deterioration of immune function that accompanies aging. Thymosin Alpha-1 is a defined single peptide with strong clinical data for immune indications. Thymalin is a complex extract from the same conceptual tradition, developed within the same Russian research program as Epithalon and Pinealon. The Khavinson bioregulator program deserves acknowledgment as a coherent long-term research effort even as its methodological limitations require honest disclosure.
FOXO4-DRI represents the most mechanistically novel compound in this cluster—a senolytic rather than a trophic or modulatory agent. Where most compounds here seek to support aging tissue, FOXO4-DRI seeks to selectively eliminate senescent cells that impair it. The 2017 mouse data is the most cited preclinical result in the longevity peptide space. It is also, as of this writing, the only robust evidence that exists. The community self-experimentation that has followed that paper is occurring entirely without human pharmacokinetic or safety data.
Klotho peptides occupy a different category: the observational evidence for the klotho protein as a longevity-associated biomarker is strong and independently replicated. The step from that observational biology to therapeutic klotho-derived peptide fragments is large and has not been bridged in human trials. This is the pattern that recurs throughout longevity research—compelling biology, credible hypothesis, and a clinical evidence base that has not caught up.